Lilly's second-quarter results reported Thursday were still more than fine: $15.5 billion in revenue beat Wall Street estimates.

Here’s everything to know about the end of Weapons. Weapons opens with a voiceover from a female student at Maybrook ...

Key Takeaways A new daily pill helped people lose an average of 27 poundsThe pill may be easier to make and use than injectable weight loss drugsSide effects were mostly stomach-related, like vomiting ...

The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst ...

In May, it announced it would acquire SiteOne Therapeutics, a drugmaker with a promising investigational medicine for pain.

Good morning. Today, we read about the implications of mRNA funding cuts on national security, see layoffs at gene-editing ...

The Trump administration has been talking to drugmakers about ways to raise prices of medicines in Europe and elsewhere to ...

Learn about July 2025’s top biotech deals, featuring major collaborations in small molecules, antibodies, and drug delivery.

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

Eli Lilly’s orforglipron cut body weight to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ ...

Eli Lilly said it plans to submit the pill to the Food and Drug Administration for approval as a weight loss medication this ...

Lilly King spent the last two days of her professional swimming career doing what she’s done so well for the last decade.